Acute Phase Protein Response and Polymorphonuclear Leukocyte Cathepsin G Release After Slow Interleukin-1 Stimulation in the Rat

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 1994 Jan 1

PMID 18475591

Citations 1

Authors

P Bjork

T Gudmundsson

K Ohlsson

Affiliations

Soon will be listed here.

Abstract

In this work we have studied the acute phase protein response and degranulation of polymorphonuclear leukocytes in vivo in the rat after a slow interleukin-1beta stimulation. A total dose of 1 mug, 2 mug, 4 mug and 0 mug (controls with only vehicle) of interleukin-1beta was released from osmotic minipumps over a period of 7 days. The pumps were implanted subcutaneously. A cystic formation was formed around the pumps that contained interleukin-1beta whereas no tissue reaction was seen around pumps containing only vehicle. Besides flbroblasts the cyst wall contained numerous polymorphonuclear leukocytes which were positively stained for cathespin G. alpha(2)-macroglobulin, alpha(1)-inhtbitor-3, alpha(1)-proteinase inhibitor, albumin and C3 were measured by electroimmunoassay and all showed plasma concentration patterns that were dose-dependent to the amount of interleuktn-1beta released. Fibrinogen in plasma was elevated in the control group but showed decreased plasma values with higher doses of interleukin-1beta released. All animals showed increased plasma levels of cathespin G but the lowest levels for cathespin G were seen for the highest interleukin-1beta dose released. It was clearly seen that a slow continuous release of interleukin-1beta in vivo caused an inflammatory reaction. Plasma levels for the proteins analysed all showed a similar pattern, namely an initial increase or decrease of plasma concentration followed by a tendency to normalization of plasma values. It was concluded that a long-term interleukin-1beta release could not sustain the acute phase protein response elicited by the initial interleukin-1beta release.

Citing Articles

alpha(2)-macroglobulin and alpha(1)-inhibitor-3 mRNA expression in the rat liver after slow interleukin-1 stimulation.

Gudmundsson T, Bjork P, Ohlsson K Mediators Inflamm. 1996; 5(4):266-70.

PMID: 18475738 PMC: 2365808. DOI: 10.1155/S0962935196000385.

References

Pizzo S, Mast A, Feldman S, Salvesen G . In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim Biophys Acta. 1988; 967(2):158-62. DOI: 10.1016/0304-4165(88)90005-0. View

Croute F, Delaporte E, Bonnefoy J, Fertin C, Thivolet J, Nicolas J . Interleukin-1 beta stimulates fibroblast elastase activity. Br J Dermatol. 1991; 124(6):538-41. DOI: 10.1111/j.1365-2133.1991.tb04946.x. View

Bjrok P, Ohlsson K . The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse. Mediators Inflamm. 1992; 1(1):27-31. PMC: 2365324. DOI: 10.1155/S0962935192000061. View

Eisenberg S, Evans R, Arend W, VERDERBER E, Brewer M, Hannum C . Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 1990; 343(6256):341-6. DOI: 10.1038/343341a0. View

Granowitz E, Clark B, Mancilla J, Dinarello C . Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem. 1991; 266(22):14147-50. View

Dinarello C . Interleukin-1 and its biologically related cytokines. Adv Immunol. 1989; 44:153-205. DOI: 10.1016/s0065-2776(08)60642-2. View

Hannum C, Wilcox C, Arend W, Joslin F, Dripps D, Heimdal P . Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990; 343(6256):336-40. DOI: 10.1038/343336a0. View

LAURELL C . Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972; 124:21-37. DOI: 10.3109/00365517209102748. View

Dunn C, Hardee M, Staite N . Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and Ifn gamma in mice. Agents Actions. 1989; 27(3-4):290-3. DOI: 10.1007/BF01972801. View

10.

de Jong F, Birch H, Schreiber G . Effect of recombinant interleukin-1 on mRNA levels in rat liver. Inflammation. 1988; 12(6):613-7. DOI: 10.1007/BF00914322. View

11.

Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson R . Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990; 348(6301):550-2. DOI: 10.1038/348550a0. View

12.

CARTER D, Deibel Jr M, Dunn C, Tomich C, Laborde A, Slightom J . Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature. 1990; 344(6267):633-8. DOI: 10.1038/344633a0. View

13.

Gauthier F, Ohlsson K . Isolation and some properties of a new enzyme-binding protein in rat plasma. Hoppe Seylers Z Physiol Chem. 1978; 359(8):987-92. DOI: 10.1515/bchm2.1978.359.2.987. View

14.

Tilg H, Trehu E, Atkins M, Dinarello C, Mier J . Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994; 83(1):113-8. View

15.

Nakajima K, POWERS J, Ashe B, Zimmerman M . Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem. 1979; 254(10):4027-32. View

16.

Gauthier F, MOURAY H . Rat alpha2 acute-phase macroglobulin. Isolation and physicochemical properties. Biochem J. 1976; 159(3):661-5. PMC: 1164166. DOI: 10.1042/bj1590661. View

17.

KAMPSCHMIDT R, UPCHURCH H . Effect of leukocytic endogenous mediator on plasma fibrinogen and haptoglobin. Proc Soc Exp Biol Med. 1974; 146(3):904-7. DOI: 10.3181/00379727-146-38216. View

18.

LONBERG-HOLM K, Reed D, Roberts R, Hebert R, Hillman M, Kutney R . Three high molecular weight protease inhibitors of rat plasma. Isolation, characterization, and acute phase changes. J Biol Chem. 1987; 262(1):438-45. View

19.

Scuderi P, Nez P, Duerr M, Wong B, Valdez C . Cathepsin-G and leukocyte elastase inactivate human tumor necrosis factor and lymphotoxin. Cell Immunol. 1991; 135(2):299-313. DOI: 10.1016/0008-8749(91)90275-g. View

20.

Zoja C, Wang J, Bettoni S, Sironi M, Renzi D, Chiaffarino F . Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol. 1991; 138(4):991-1003. PMC: 1886116. View